Your favorite alcoholic beverage could be linked to deadly form of cancer, study finds
Following the surgeon general's January advisory linking alcohol consumption to seven types of cancer, a new study from the International Agency for Research on Cancer (IARC) has revealed another possible risk.
The research, which was recently published in the journal PLOS Medicine, classified alcohol as a carcinogen, highlighting a particular increased risk of pancreatic cancer.
The surgeon general's previous advisory named cancers of the breast (in women), colorectum, esophagus, voice box, liver, mouth and throat.
The researchers associated the pancreatic cancer risk with beer and spirits/liquor, but not with the intake of wine.
"Alcohol consumption is a known carcinogen, but until now, the evidence linking it specifically to pancreatic cancer has been considered inconclusive," said senior study author Dr. Pietro Ferrari, head of the IARC Nutrition and Metabolism Branch, in a press release.
"Our findings provide new evidence that pancreatic cancer may be another cancer type associated with alcohol consumption, a connection that has been underestimated until now."
For the study, researchers recruited 2.5 million participants with a median age of 57, following them for about 16 years.
Out of the group, 10,067 cases of pancreatic cancer were recorded.
Each increase of 10 grams of ethanol per day in alcohol consumption was associated with a 3% increase in the risk of pancreatic cancer, the study found.
Women who consumed 15 to 30 grams of alcohol (about one to two standard drinks) per day had a 12% increase in pancreatic cancer risk.
Men who consumed 30 to 60 grams (two to six standard drinks) per day had a 15% increased risk of pancreatic cancer, and intake of over 60 grams per day was associated with a 36% greater risk.
"There really isn't a safe level of drinking when it comes to cancer risk."
The research did have some limitations.
"This observational study examined alcohol intake evaluated at a single time point during mid-to-late adulthood and included a limited number of Asian cohorts," the researchers wrote.
"Further research is needed to better understand the role of lifetime alcohol consumption — for example, during early adulthood — and the influence of specific consumption patterns, such as binge-drinking."
Dr. Adam Scioli, an addiction psychiatrist at Caron Treatment Centers in Pennsylvania, previously commented to Fox News Digital that "alcohol is a toxin."
"There have been reports for years that it could be beneficial for one's health — but we know now that alcohol ingestion is one of the modifiable risk factors for cancer," Scioli, who is not affiliated with IARC, told Fox News Digital.
Dr. Marc Siegel, senior medical analyst for Fox News, was not involved in the study, but spoke with Fox News Digital about the findings.
"This is in keeping with alcohol as a toxin that directly inflames and damages pancreatic cells," he confirmed.
Around 75,000 Americans each year are diagnosed with a cancer that is in some way linked to alcohol use, according to Scioli.
Dr. Neha Pathak, WebMD's chief physician editor of health and lifestyle medicine, noted that the study highlights a new, independent risk factor for pancreatic cancer.
"What's important to know is that there really isn't a safe level of drinking when it comes to cancer risk," Atlanta-based Pathak, who also did not participate in the research, told Fox News Digital.
For more Health articles, visit www.foxnews.com/health
"This study reinforces that message — but it also shows how complex these links are, and how we need to keep digging deeper into the role of alcohol and different drinking habits in cancer development," she added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an 'Outperform' rating and a $49 price target. The research firm reiterated the company's solid position amid the 'TTR craze' while also echoing its commercial execution strategy. A medical technician wearing a lab coat operating machinery in a biopharmaceutical laboratory. Consequently, Wolfe Research expects BridegBio's revenue to total $569 million in 2025 before rising to $3.4 billion by 2028. It should peak at $4.4 billion in 2034. For the upcoming second quarter, the research firm expects the company to deliver revenue of $106 million, slightly below market expectation of $111 million. While the stock has shown a remarkable return of 42% year to date, Wolfe Research insists it must navigate several challenges to maintain the positive momentum. It must navigate the potential Vyndaqel loss of exclusivity, achondroplasia data versus competition, and pipeline products. In addition, consistent revenue growth and expanding operating margins will be crucial to the company's long-term success. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases. Its pipeline includes a range of development programs, from early science to advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio
Yahoo
44 minutes ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
Yahoo
44 minutes ago
- Yahoo
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
